EDINBURGH, Scotland and LONDON, Dec. 10, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering regenerative ...
– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis – Dr Lara Campana ...
– Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation – The first is a late-breaking abstract showcasing extended follow-up data from the ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
– Oral Presentation of complete data from the three-year MATCH Phase 2 trial EDINBURGH, Scotland and LONDON, Oct. 1, 2024 Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage ...
– Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation – – Poster presentation on new data highlighting the Company's discovery platform to ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024 PR Newswire EDINBURGH, Scotland and LONDON, Oct. 1, ...
The MarketWatch News Department was not involved in the creation of this content. Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback